{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:36:28Z","timestamp":1761896188544},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T00:00:00Z","timestamp":1453939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00280-015-2954-x","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T13:48:01Z","timestamp":1453988881000},"page":"559-564","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy"],"prefix":"10.1007","volume":"77","author":[{"given":"Yusuke","family":"Takagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nagamata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kageaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Yomota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniko","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneo","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuru","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,28]]},"reference":[{"issue":"2","key":"2954_CR1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1535-7163.MCT-06-0343","volume":"6","author":"S Chattopadhyay","year":"2007","unstructured":"Chattopadhyay S, Moran RG, Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6(2):404\u2013417","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2954_CR2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1634\/theoncologist.6-4-363","volume":"6","author":"AR Hanauske","year":"2001","unstructured":"Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001) Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6(4):363\u2013373","journal-title":"Oncologist"},{"issue":"5","key":"2954_CR3","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s002800050992","volume":"44","author":"DA Rinaldi","year":"1999","unstructured":"Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Jones S, Woodworth JR, Baker S, Langley C, Mascorro D, Abrahams T, Von Hoff DD (1999) A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21\u00a0days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44(5):372\u2013380","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2954_CR4","first-page":"545","volume":"1","author":"C Niyikiza","year":"2002","unstructured":"Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, Stabler SP, Paoletti P, Calvert AH, Allen RH (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1(7):545\u2013552","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"2954_CR5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636\u20132644","journal-title":"J Clin Oncol"},{"issue":"6","key":"2954_CR6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1634\/theoncologist.10-6-363","volume":"10","author":"MH Cohen","year":"2005","unstructured":"Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R (2005) FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 10(6):363\u2013368","journal-title":"Oncologist"},{"issue":"11","key":"2954_CR7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1634\/theoncologist.2014-0221","volume":"19","author":"Y Takagi","year":"2014","unstructured":"Takagi Y, Hosomi Y, Sunami K, Nakahara Y, Okuma Y, Yomota M, Shimokawa T, Nagamata M, Iguchi M, Okamoto H, Okamura T, Shibuya M (2014) A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer. Oncologist 19(11):1194\u20131199","journal-title":"Oncologist"},{"issue":"10","key":"2954_CR8","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/archinte.165.10.1167","volume":"165","author":"SJ Eussen","year":"2005","unstructured":"Eussen SJ, de Groot LC, Clarke R, Schneede J, Ueland PM, Hoefnagels WH, van Staveren WA (2005) Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. Arch Intern Med 165(10):1167\u20131172","journal-title":"Arch Intern Med"},{"issue":"4","key":"2954_CR9","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood.V92.4.1191","volume":"92","author":"AM Kuzminski","year":"1998","unstructured":"Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J (1998) Effective treatment of cobalamin deficiency with oral cobalamin. Blood 92(4):1191\u20131198","journal-title":"Blood"},{"issue":"5","key":"2954_CR10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood.V9.5.473.473","volume":"9","author":"GI Ross","year":"1954","unstructured":"Ross GI, Mollin DL, Cox EV, Ungley CC (1954) Hematologic responses and concentration of vitamin B12 in serum and urine following oral administration of vitamin B12 without intrinsic factor. Blood 9(5):473\u2013488","journal-title":"Blood"},{"key":"2954_CR11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2296-12-2","volume":"12","author":"B Favrat","year":"2011","unstructured":"Favrat B, Vaucher P, Herzig L, Burnand B, Ali G, Boulat O, Bischoff T, Verdon F (2011) Oral vitamin B12 for patients suspected of subtle cobalamin deficiency: a multicentre pragmatic randomised controlled trial. BMC Fam Pract 12:2","journal-title":"BMC Fam Pract"},{"issue":"13","key":"2954_CR12","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-07-5143","volume":"14","author":"Y Ohe","year":"2008","unstructured":"Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y, Saijo N, Fukuoka M (2008) Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 14(13):4206\u20134212","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2954_CR13","doi-asserted-by":"crossref","first-page":"e59700","DOI":"10.1371\/journal.pone.0059700","volume":"8","author":"Y Takagi","year":"2013","unstructured":"Takagi Y, Toriihara A, Nakahara Y, Yomota M, Okuma Y, Hosomi Y, Shibuya M, Okamura T (2013) Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study. PLoS ONE 8(3):e59700","journal-title":"PLoS ONE"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2954-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2954-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2954-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T14:20:27Z","timestamp":1600093227000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2954-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,28]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["2954"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2954-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,28]]}}}